3. HISTORY OF GCP
3
Year Milestone
460BC Oath of Hippocrates
1930's U.S. Food, Drugs and Cosmetic Act
1947 NurembergCode
Dec. 10th 1948 Declaration of Human Rights
1962 Kefauver-Harris Amendment
1964, revised 2000 Declaration of Helsinki
1979 The Belmont Report
1982 International Guidelines for Biomedical Research InvolvingHuman Subjects
1996 ICH-GCP guidelines issued
1997 ICH-GCP guidelines becomes law in some countries
4. HISTORY OF GCP (CONT..)
• The concept of the ‘good physician‘ dates back to the ancient world and it
is evidenced by the Hippocratic Oath (460 BC).
4
5. HISTORY OF GCP (CONT..)
• In the United States, the first landmark in the regulation of drugs was the Food and
Drugs Act of 1906.
• It is considered to be the result of very dangerous and even deadly drugs that could
have been sold legally just like any other medical goods.
• For example, such drugs were ‘Grandma’s Secret’ and ‘Kopp’s Baby’s Friend’, which
contained a huge amount of morphine. ‘Dr. King’s Consumption Cure’ and ‘Dr. Bull’s
Cough Syrup‘ are examples of drugs which had large doses of morphine and
chloroform as well.
5
6. • Have you ever wondered what clinical trials are and how they are conducted? This web seminar is designed
to answer those basic questions. We will look at how drugs progress from discovery to testing in humans,
and learn what it takes to obtain approval to treat a disease or condition. we will review how Good Clinical
Practice (GCP) is applied to clinical trials around the world and how it is designed to protect clinical trial
participants and ensure that the information obtained during a clinical trial is accurate and reliable.
6
7. JAMES LIND
In 1747, the first ever clinical
trial, he developed the theory
that citrus fruits cured scurvy.
7
8. • Scurvy is a disease resulting from a lack of vitamin C (ascorbic acid). Early
symptoms of deficiency include weakness, feeling tired and sore arms and
legs. Without treatment, decreased red blood cells, gum disease, changes
to hair, and bleeding from the skin may occur.
• Other names: Moeller's disease, Cheadle's dis...
• Symptoms: Weakness, feeling tired, changes to ...
• Treatment: Vitamin C supplements, Citrus fruits
• Causes: Lack of vitamin C
8
9. 9
James Lind is considered the first physician to have conducted a controlled clinical trial
of the modern era. Dr Lind (1716-94), whilst working as a surgeon on a ship, was appalled
by the high mortality of scurvy amongst the sailors. He planned a comparative trial of the
most promising cure for scurvy. His vivid description of the trial covers the essential elements of
a controlled trial.
For 18th Century sailors, disease during long sea voyages was often more
dangerous than enemy action. James Lind is described by the Royal Navy as "the
father of naval medicine"
10. • This brings us to James Lind and his scurvy “clinical trial”. The year
is 1747 and Lind, a surgeon on a ship decides to test out the most
promising cures for scurvy, describing a process closely resembling
our modern day controlled clinical trials. He chose a group of similar
cases on one and the same diet and gave different medicine in pairs
– cider, vitriol, vinegar, sea water, oranges, and lemons. Of course,
as you know, the oranges and lemons “won” with the cider following
closely but here’s what happened next: oranges were far too
expensive to be recommended as treatment despite the high levels
of mortality. It was another 50 years before the British Navy supplied
every overseas journey with lemon juice and even then the lemons
were eventually replaced by the much cheaper at that time limes.
10
11. 11
Lind describes“”On the 20th of May 1747, I selected twelve patients in the scurvy, on board the Salisbury
at sea. Their cases were as similar as I could have them. They all in general had putrid gums, the spots
and lassitude, with weakness of the knees. They lay together in one place, being a proper apartment for
the sick in the fore-hold; and had one diet common to all, viz. water gruel sweetened with sugar in the
morning; fresh mutton-broth often times for dinner; at other times light puddings, boiled biscuit with sugar,
etc., and for supper, barley and raisins, rice and currants, sago and wine or the like. Two were ordered
each a quart of cyder a day. Two others took twenty-five drops of elixir vitriol three times a day … Two
others took two spoonfuls of vinegar three times a day … Two of the worst patients were put on a course
of sea-water … Two others had each two oranges and one lemon given them every day … The two
remaining patients, took … an electary recommended by a hospital surgeon … The consequence was,
that the most sudden and visible good effects were perceived from the use of oranges and lemons; one of
those who had taken them, being at the end of six days fit for duty … The other was the best recovered of
any in his condition; and … was appointed to attend the rest of the sick. Next to the oranges, I thought the
cyder had the best effects …” (Dr James Lind's “Treatise on Scurvy” published in Edinburgh in 1753).In
1747, on board HMS Salisbury, he carried out one of the first controlled clinical trials recorded in medical
science.
12. 12
He took 12 men suffering from similar symptoms of scurvy, divided them into six pairs and
treated them with remedies suggested by previous writers:
a quart of cider a day
25 drops of elixir of vitriol, three times a day
half a pint of sea-water a day
a nutmeg-sized paste of garlic, mustard seed, horse-radish, balsam of Peru, and gum myrrh
three times a day
two spoonfuls of vinegar, three times a day
two oranges and one lemon a day
By the end of the week, those on citrus fruits were well enough to nurse the others.
However, in the Royal Navy, Dr Lind is remembered as a hero.
In summary, the history of scurvy in the British Navy during the second half of the 18th
century shows how comparative clinical trials in controlled conditions of time and
environment were well described by Lind, yet, initially for understandable reasons,
imperfectly translated into practice, and only on a very small scale. James Lind is
remembered as the man who helped to conquer a killer disease. His reported
experiment on board a naval ship in 1747 showed that oranges and lemons were a
cure for scurvy.
13. • The Tuskegee experiment began in 1932, at a time when there was no known treatment for
syphilis. After being recruited by the promise of free medical care, 600 men originally were
enrolled in the project for free medical care and treatment instead it was a secret study to study
the impact and progress of syphilis (Syphilis is a bacterial infection usually spread by sexual
contact. The disease starts as a painless sore — typically on your genitals, rectum or
mouth. Syphilis spreads from person to person via skin or mucous membrane contact with these
sores)on human body
• The participants were primarily sharecroppers, and many had never before visited a doctor.
Doctors from the U.S. Public Health Service (PHS), which was running the study, informed the
participants—399 men with latent syphilis and a control group of 201 others who were free of the
disease—they were being treated for bad blood, a term commonly used in the area at the time to
refer to a variety of ailments.and diseases The men were monitored by health workers but only
given placebos such as aspirin and mineral supplements, despite the fact penicillin became the
recommended treatment for syphilis in 1947. PHS researchers convinced local physicians in
Macon County not to treat the participants, and research was done at the Tuskegee Institute.
(Now called Tuskegee University, the school was founded in 1881 with Booker T. Washington at
its first teacher.)
13
Tuskegee Syphilis Study (1932)
14. • In 1932, the USPHS, working with the Tuskegee Institute, began a study to
record the natural history of syphilis. It was originally called the “Tuskegee
Study of Untreated Syphilis in the Negro Male” (now referred to as the
“USPHS Syphilis Study at Tuskegee”). The study initially involved 600 Black
men – 399 with syphilis, 201 who did not have the disease. Participants’
informed consent was not collected. Researchers told the men they were
being treated for “bad blood,” a local term used to describe several ailments,
including syphilis, anemia, and fatigue. In exchange for taking part in the
study, the men received free medical exams, free meals, and burial
insurance
• In order to track the disease’s full progression, researchers provided no
effective care as the men died, went blind or insane or experienced other
severe health problems due to their untreated syphilis.
• In the mid-1960s, a PHS venereal disease investigator in San Francisco
named Peter Buxton found out about the Tuskegee study and expressed his
concerns to his superiors that it was unethical. In response, PHS officials
formed a committee to review the study but ultimately opted to continue it,
with the goal of tracking the participants until all had died, autopsies were
performed and the project data could be analyzed.
14
15. 15
In 1972, an Associated Press story external icon about the study was published As a result, the
story wasv leaked to a reporter friend, who passed it on to a fellow reporter, Jean Heller of the
Associated Press. Heller broke the story in July 1972, prompting public outrage and forcing the
study to shut down. In October 1972, the panel advised stopping the study. A month later, the
Assistant Secretary for Health and Scientific Affairs announced the endexternal icon of the study.
By that time, 28 participants had perished from syphilis, 100 more had passed away from related
complications, at least 40 spouses had been diagnosed with it and the disease had been passed
to 19 children at birth.
Later in 1973, a class-action lawsuit was filed on behalf of the study participants and their
families, resulting in a $10 million, out-of-court settlement in 1974.
On May 16, 1997, President Bill Clinton issued a formal Presidential Apology external icon for the
study.
Tuskegee Syphilis Study (1932)
16. OUTCOME OF TUSKEGEE SYPHILIS STUDY
• Men involved had agreed freely to be examined & treated.
• There was no evidence that researchers had informed them of the study
or its real purpose.
• In fact, the men had been misled and had not been given all the facts
required to provide informed consent.
• The men were never given adequate treatment for their disease. Even
when penicillin became the drug of choice for syphilis in 1947
• 1973-Congress holds hearings and a class-action lawsuit is filed on
behalf of the study participants. A $10 million out-of-court settlement is
reached.
16
17. 17
Sulfanilamide, a drug used to treat streptococcal infections, had been shown to have dramatic
curative effects and had been used safely for some time in tablet and powder form. Elixir
sulfanilamide was an improperly prepared sulfanilamide medicine that caused
mass poisoning in the United States in 1937. It caused the deaths of more than 100
people. The public outcry caused by this incident and other similar disasters led to the passing
of the 1938 Federal Food, Drug, and Cosmetic Act, which significantly increased the Food and
Drug Administration's powers to regulate drugs
In 1937, S.E Massengill Company , a pharmaceutical manufacturer, created a preparation
of sulfanilamide using diethylene glycol (DEG) as a solvent, and called the preparation "Elixir
Sulfanilamide".[3] DEG is poisonous to humans and other mammals, but Harold Watkins, the
company's chief pharmacist and chemist, was not aware of this. (Though the first case of a
fatality from ethylene glycol occurred in 1930 and studies had been published in medical journals
stating DEG could cause kidney damage or failure, its toxicity was not widely known prior to the
incident.)[Watkins simply added raspberry flavoring to the sulfa drug which he had dissolved in
DEG and the company S.E Massengill then marketed the product.
Animal testing was not required by law, and Massengill performed none; there were no
regulations requiring premarket safety testing of new drugs.
The company started selling and distributing the medication in September 1937. By October 11,
the American Medical Association received a report of several deaths caused by the medication.
The Food and Drug Administration was notified, and an extensive search was conducted to
recover the distributed medicine.[5] Frances Oldham Kelsey assisted on a research project that
verified that the excipient DEG was responsible for the fatal adverse effects. At least 100 deaths
were blamed on the medication.
ELIXIR SULFANILAMIDE DISASTER_1937
19. ELIXIR SULFANILAMIDE DISASTER_1937
• The US Food and Drug Administration’s role in the regulation of novel
medicines was born out of tragedy. Seventy-one adults and 34 children
died in the fall of 1937 after taking a drug called Elixir Sulfanilamide to
treat a variety of ailments, from gonorrhea to sore throat. At that time,
the FDA, which had been launched in 1906 as the Bureau of Chemistry,
served simply to police claims made about food and drug ingredients.
No formal government approval was required to market new drugs.
• The disaster provoked a public outcry that led to the passage of the
1938 Food, Drug, and Cosmetics Act, which gave the FDA power to
monitor the safety of new drugs. That all changed in 1938, after the
deaths linked to Elixir Sulfanilamide had become a national scandal
19
20. Food, Drug, and Cosmetic Act (1938)
which required companies to perform animal safety tests on their proposed new drugs
and submit the data to the FDA before being allowed to market their products.
The Federal Food, Drug, and Cosmetic Act was passed by Congress in 1938 in
reaction to the growing public safety demands. The primary goal of the Act is to
protect the health and safety of the public by preventing deleterious, adulterated or
misbranded articles from entering interstate commerce. The United States Federal
Food, Drug, and Cosmetic Act (abbreviated as FFDCA, FDCA, or FD&C), is a
set of laws passed by Congress in 1938 giving authority to the U.S. Food and Drug
Administration (FDA) to oversee the safety of food, drugs, medical devices, and
cosmetics. The introduction of this act was influenced by the death of more than
100 patients due to a sulfanilamide medication where diethylene glycol was used
to dissolve the drug and make a liquid form[4] (see elixir sulfanilamide disaster). It
replaced the earlier Pure Food and Drug Act of 1906.
20
21. HISTORY-NUREMBERG TRIAL AND CODE
• The Code was formulated 50 years ago, in August 1947, in Nuremberg, Germany, by
American judges sitting in judgment of Nazi doctors accused of conducting murderous and
torturous human experiments in the concentration camps (the so-called Doctors' Trial).
• During the Second World War a number of severe unethical experiments were carried out by
researchers affiliated with the Nazi party in Germany. Patients with a physical and/or mental
disability and prisoners of war were forcibly experimented upon to gather information about
racial characteristics and genetics. These experiments were investigated, and the doctors
prosecuted in the Nuremberg Trials and, more specifically, the Doctor Trials which began in
1947. A victim of a Nazi medical experiment is immersed in icy water to test reactions to
hyperthermia. SS doctor Sigmund Rancher oversees the experiment. The Nuremberg
trials (German: Nürnberger Prozesse) were a series of military tribunals held after World War
II by the Allied forces under international law and the laws of war. The trials were most notable
for the prosecution of prominent members of the political, military, judicial, and economic
leadership of Nazi Germany, who planned, carried out, or otherwise participated in the
Holocaust and other war crimes. The trials were held in Nuremberg, Germany, and their
decisions marked a turning point between classical and contemporary international law.
21
23. NUREMBERG CODE
Held for the purpose of bringing Nazi war criminals to justice, the Nuremberg trials were a series of 13 trials carried out in
Nuremberg, Germany, between 1945 and 1949. The defendants, who included Nazi Party officials and high-ranking military
officers along with German industrialists, lawyers and doctors, were indicted on such charges as crimes against peace and
crimes against humanity. Nazi leader Adolf Hitler (1889-1945) committed suicide and was never brought to trial. On
December 9, 1946, an American military tribunal opened criminal proceedings against 23 leading German physicians and
administrators for their willing participation in war crimes and crimes against humanity. This case is known as the "Doctors
Trial" (USA v. Karl Brandt et. al). On August 19, 1947, the judges of the tribunal delivered their verdict. But before
announcing the guilt or innocence of each defendant, they confronted the difficult question of medical experimentation on
human beings.
Several German doctors had argued in their own defense that their experiments differed little from those conducted before
the war by German and American scientists. Furthermore they showed that no international law or informal statement
differentiated between legal and illegal human experimentation. This argument was a great concern to two US doctors who
had worked with the prosecution during the trial, Dr. Andrew Ivy and Dr. Leo Alexander.
As a result, on April 17, 1947, Dr. Alexander submitted a memorandum to the United States Counsel for War Crimes. The
memo outlined six points that defined legitimate medical research. The trial's verdict of August 19 reiterated almost all of
these points in a section entitled "Permissible Medical Experiments." It also revised the original six points into ten, and
these the ten points became known as the "Nuremberg Code."
23
24. NUREMBERG CODE
• In 1947, the Nuremberg Code was created as a result of the unethical and horrific experiments carried out during World
War II at Nazi war camps by German physicians, who were subsequently tried and charged at the Nuremberg Military
Tribunal. This code states the need for a scientific basis in research on human subjects and voluntary consent and
protection of participants. The Nuremberg Code (German: Nürnberger Kodex) is a set of research ethics principles
for human experimentation created as a result of the Nuremberg trials at the end of the Second World War.
The Code was formulated 50 years ago, in August 1947, in Nuremberg, Germany, by American judges sitting in
judgment of Nazi doctors accused of conducting murderous and torturous human experiments in the concentration camps
(the so-called Doctors' Trial).
24
25. NUREMBERG CODE
1. The voluntary consent of the human subject is absolutely essential.
2. The experiment should be such as to yield fruitful results for the good of society, unprocurable by other methods or
means of study, and not random and unnecessary in nature.
3. The experiment should be so designed and based on the results of animal experimentation and a knowledge of the
natural history of the disease or other problem under study that the anticipated results will justify the performance of
the experiment.
4. The experiment should be so conducted as to avoid all unnecessary physical and mental suffering and injury.
5. No experiment should be conducted where there is an a priori reason to believe that death or disabling injury will
occur; except, perhaps, in those experiments where the experimental physicians also serve as subjects.
6. The degree of risk to be taken should never exceed that determined by the humanitarian importance of the problem
to be solved by the experiment..
7. Proper preparations should be made and adequate facilities provided to protect the experimental subject against even
remote possibilities of injury, disability, or death.
8. The experiment should be conducted only by scientifically qualified persons. The highest degree of skill and care
should be required through all stages of the experiment of those who conduct or engage in the experiment.
9. During the course of the experiment the human subject should be at liberty to bring the experiment to an end if he has
reached the physical or mental state where continuation of the experiment seems to him to be impossible.
10. During the course of the experiment the scientist in charge must be prepared to terminate the experiment at any
stage, if he has probable cause to believe, in the exercise of the good faith, superior skill and careful judgment
required of him that a continuation of the experiment is likely to result in injury, disability, or death to the experimental
subject.
25
26. UNIVERSAL DECLARATION OF
HUMAN RIGHTS
• The Universal Declaration of Human Rights is a historic document
which outlined the rights and freedoms everyone is entitled to. It was
the first international agreement on the basic principles of human
rights. It laid the foundation for the human rights protections that we
have in the UK today. The Universal Declaration of Human Rights,
which was adopted by the UN General Assembly on 10 December
1948, was the result of the experience of the Second World War.
The Universal Declaration includes civil and political rights, like
the right to life, liberty, free speech and privacy. It also includes
economic, social and cultural rights, like the right to social security,
health and education.
26
27. THALIDOMIDE DISASTER_1962
• The Thalidomide disaster is one of the darkest episodes in pharmaceutical research history. The drug
was marketed as a mild sleeping pill safe even for pregnant women. However, it caused thousands of
babies worldwide to be born with malformed limbs. The damage was revealed in 1962. Many children
in the 1960's, like the kindergartner pictured above, were born with phocomelia as a side effect of the
drug thalidomide, resulting in the shortening or absence of limbs. Thalidomide first entered the
German market in 1957 as an over-the-counter remedy, based on the maker’s safety claims. They
advertised their product as “completely safe” for everyone, including mother and child, “even during
pregnancy,” as its developers “could not find a dose high enough to kill a rat.” By 1960, thalidomide
was marketed in 46 countries, with sales nearly matching those of aspirin.
27
28. • The Thalidomide disaster is one of the tragic events which happened in the
history of medical research field. This disaster resulted in the rules becoming
more stringent for the pharmaceutical industries
• Initially, Thalidomide drug was marketed as a mild sleeping pill. Later, it was
found that Thalidomide could also be used safely against nausea. And hence,
healthcare professionals started prescribing the drug to pregnant women to relief
them from morning sickness symptom.
• Thalidomide was widely used in late 1950s and early 1960s. However, the drug
caused unexpected and serious damage to thousands of unborn babies
worldwide. The consumption of drug by pregnant women during pregnancy
(especially first four to eight weeks) lead to birth of babies with birth defects such
as deafness, blindness, disfigurement, cleft palate, phocomelia (bilateral
shortened limbs) and other defects. It even caused deaths of many. Babies
affected by this disaster were called “Thalidomide Babies”. The whole damage
was noticed in 1960s post which the drug Thalidomide was banned immediately.
28
29. KEFAUVER HARRIS AMENDMENT (1962) BY US
CONGRESS
"DRUG EFFICACY AMENDMENT"
•
The Kefauver Harris Amendment strengthened the U.S. Food and Drug Administration's
control of experimentation on humans and changed the way new drugs are approved and
regulated. Before the Thalidomide scandal in Europe, and Canada, U.S. drug companies
only had to show their new products were safe.
• The amendment was a response to the Thalidomide tragedy. It introduced a "proof-of-
efficacy" requirement, that was not present before. In addition, the Amendment required drug
advertising to disclose accurate information about side effects and efficacy of treatments.
Finally, cheap generic drugs could no longer be marketed as expensive drugs under new
trade names as new "breakthrough" medications, as they were prior to the amendment. It
introduced a requirement for drug manufacturers to provide proof of the effectiveness and
safety of their drugs before approval, It is required for drug advertising to disclose accurate
information about side effects, and stopped cheap generic drugs being marketed as
expensive drugs under new trade names as new "breakthrough" medications. The U.S.
Supreme Court determined that generic drugs are new drugs. The efficacy
requirement was applied to drugs marketed between 1906 and 1962. ... The FDA will
approve the product as GRASE (generally recognized as safe and effective) and not a
new drug. 29
30. DECLARATION OF HELSINKI_1964
The Declaration of Helsinki was adopted in 1964 by the 18th WMA General Assembly,
at Helsinki. This is a set of ethical principles regarding human experimentation developed
for the medical community by the World Medical Association (WMA). It is widely regarded
as the cornerstone document on human research ethics. Declaration of Helsinki, formal
statement of ethical principles published by the World Medical Association (WMA) to guide
the protection of human participants in medical research. The 2013
version of the Declaration of Helsinki is the only one that is officially recognized by the
World Medical Association; all of the prior versions were replaced by the 2013 versions and
they should only be used for historical purposes. The World Medical
Association's Declaration of Helsinki was first adopted in 1964. In its 40-year lifetime
the Declaration has been revised five times and has risen to a position of prominence as
a guiding statement of ethical principles for doctors involved in medical research.
“The World Medical Association has developed the Declaration of Helsinki as a statement of ethical principles to provide
guidance to physicians and other participants in medical research involving human subjects. It is the duty of the physician to
promote and safeguard the health of the people. The physician’s knowledge and conscience are dedicated to the fulfilment of
this duty”
30
31. • The health of my patient will be my first consideration,” and the International Code of
Medical Ethics declares that, “A physician shall act in the patient’s best interest when
providing medical care.”
• It is the duty of the physician to promote and safeguard the health, well-being and
rights of patients, including those who are involved in medical research. The physician’s
knowledge and conscience are dedicated to the fulfilment of this duty.
• Medical progress is based on research that ultimately must include studies
involving human subjects.
• The primary purpose of medical research involving human subjects is to understand
the causes, development and effects of diseases and improve preventive, diagnostic and
therapeutic interventions (methods, procedures and treatments). Even the best proven
interventions must be evaluated continually through research for their safety,
effectiveness, efficiency, accessibility and quality.
• Medical research is subject to ethical standards that promote and ensure respect for
all human subjects and protect their health and rights.
• While the primary purpose of medical research is to generate new knowledge, this goal
can never take precedence over the rights and interests of individual research subjects.
• It is the duty of physicians who are involved in medical research to protect the life,
health, dignity, integrity, right to self-determination, privacy, and confidentiality of
personal information of research subjects. The responsibility for the protection of
research subjects must always rest with the physician or other health care professionals
and never with the research subjects, even though they have given consent.
31
32. • Physicians must consider the ethical, legal and regulatory norms and standards for research
involving human subjects in their own countries as well as applicable international norms and
standards. No national or international ethical, legal or regulatory requirement should reduce
or eliminate any of the protections for research subjects set forth in this Declaration.
• Medical research should be conducted in a manner that minimises possible harm to the
environment.
• Medical research involving human subjects must be conducted only by individuals with the
appropriate ethics and scientific education, training and qualifications. Research on patients or
healthy volunteers requires the supervision of a competent and appropriately qualified
physician or other health care professional.
• Groups that are underrepresented in medical research should be provided appropriate access
to participation in research.
• Physicians who combine medical research with medical care should involve their patients in
research only to the extent that this is justified by its potential preventive, diagnostic or
therapeutic value and if the physician has good reason to believe that participation in the
research study will not adversely affect the health of the patients who serve as research
subjects.
• Appropriate compensation and treatment for subjects who are harmed as a result of
participating in research must be ensured.
32
33. WHO_1968 & 1975
• The World Health Organization (WHO) plays an essential role in the global governance of health and
disease; due to its core global functions of establishing, monitoring and enforcing international
norms and standards, and coordinating multiple actors toward common goals. It is responsible
for providing leadership on global health matters, shaping the health research agenda, setting norms
and standards, articulating evidence-based policy options, providing technical support to countries and
monitoring and assessing health trends.
• WHO’s International Clinical Trials Registry Platform (ICTRP) links clinical trials registers globally in
order to ensure a single point of access and the unambiguous identification of trials with a view to
enhancing access to information by patients, families, patient groups and others.
• The ICTRP is a global initiative that aims to make information about all clinical trials involving humans
publicly available. It also aims to:
• improve the comprehensiveness, completeness and accuracy of registered clinical trial data;
• communicate and raise awareness of the need to register clinical trials;
• ensure the accessibility of registered data;
• build capacity for clinical trial registration;
• encourage the utilization of registered data; and
• ensure the sustainability of the ICTRP.
33
34. BELMONT REPORT_1979
• Belmont Report was issued in April 1979 by the National Commission for Protection of Human Subjects
of Biomedical and Behavioral Research. The Belmont Report marks an important milestone in the
history of clinical research. It established guidelines for basic ethical principles, as well as informed
consent, the assessment of risks and benefits and subject selection. The report was issued on 30
September 1978. and published in the Federal Register on 18 April 1979. The report took its name from
the Belmont Conference Center where the document was drafted in part. The Belmont
Report attempts to summarize the basic ethical principles identified by the Commission in the
course of its deliberations. ... It is a statement of basic ethical principles and guidelines that should
assist in resolving the ethical problems that surround the conduct of research with human subjects. The
Belmont Report is one of the leading works concerning ethics and health care research. Its primary
purpose is to protect subjects and participants in clinical trials or research studies. This report
consists of 3 principles: beneficence, justice, and respect for persons.
• The principles of BELMONT report are as follows:
• Respect for Persons: This principle acknowledges the dignity and freedom of every person. It requires
obtaining informed consent from research subjects (or their legally authorized representatives)
• Beneficence: This principle requires that researchers maximize benefits and minimize harms
associated with research. Research-related risks must be reasonable in light of the expected benefits.
• Justice: This principle requires equitable selection and recruitment and fair treatment of research
subjects.
34
35. THERE COMES ICH
• In the 1980s the European Union began harmonising regulatory requirements. In 1989, Europe,
Japan, and the United States began creating plans for harmonisation. The International
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use (ICH) was created in April 1990 at a meeting in Brussels. ICH had the initial
objective of coordinating the regulatory activities of the European, Japanese and United States
regulatory bodies in consultation with the pharmaceutical trade associations from these regions,
to discuss and agree the scientific aspects arising from product registration.[2] Since the new
millennium, ICH's attention has been directed towards extending the benefits of harmonisation
beyond the founding ICH regions. This ICH GCP Guideline Integrated Addendum provides a
unified standard for the European Union, Japan, the United States, Australia, Canada,
the Nordic countries and the World Health Organization (WHO). to facilitate the mutual
acceptance of data from clinical trials by the regulatory authorities in these jurisdictions.
35
36. 36
The International Council(conference) for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use (ICHis an
initiative that brings together regulatory authorities and pharmaceutical industry to discuss
scientific and technical aspects of pharmaceutical product development and registration.
The mission of the ICH is to promote public health by achieving greater harmonisation
through the development of technical Guidelines and requirements for pharmaceutical
product registration. ICH Guidelines were created by The International Council for
Harmonization of Technical Requirements for Pharmaceuticals for Human Use
(ICH). ICH aims to provide uniform standards for technical requirements for
pharmaceuticals for human use. They are developed by regulatory and pharma industry
authorities.
Harmonisation leads to a more rational use of human, animal and other resources, the
elimination of unnecessary delay in the global development, and availability of new
medicines while maintaining safeguards on quality, safety, efficacy, and regulatory
obligations to protect public health.
As per the public health ICH must include the professional qualifications in their
requirements on the aspect of pharmacists must be qualified and organisations must be
included only pharmacist related of all health organisation.
37. • The formalization of the concept of harmonization led to immediate benefits to the regulatory
authorities and the pharmaceutical industry. The ICH recommendations helped in preventing
duplication of clinical trials and minimizing the use of animal testing at the same time taking
care of safety and effectiveness. The recommendations also streamlined the regulatory
process for new drug applications, thereby reducing the development times and optimizing
resources for drug development. The ICH has since then entered the electronic era with a
stress on paperless application process and sharing of real-time information among the
stakeholders. The purpose of the ICH is to “make recommendations on ways to achieve
greater harmonization on the interpretation and application of technical guidelines and
requirements for product registration in order to reduce or obviate the need to duplicate the
testing carried out during the research and development of new medicines.” From the
beginning, the ICH intended to prepare harmonized guidelines/guidances, or internationally
accepted common texts for the development of new pharmaceuticals. Harmonization was
viewed as a means of promoting efficient drug development by elimination of unnecessary
duplication and by indicating rational drug developing procedures.
• The ICH brought together representatives from regulatory authorities and experts from the
pharmaceutical industry and academia in Europe, Japan, and the United States. They
discussed scientific and technical aspects of product registration of pharmaceuticals for
human use as equal partners as well as details of the testing procedures required to ensure
the assessment of safety, quality, and efficacy of medicines and regulatory obligations to
protect public health.
37
38. • The role of ICH-GCP is to improve ethical awareness, trial concept and
methods, public safety, cost effectiveness of research and
development, competitiveness, data recognition and marketing
structure. Conducting clinical trials in accordance with ICH-GCP guidelines
has reduced the occurrence of frauds and accidents. Every trial is accessed
for risk benefit ratio, clinical design and protocol, complete information of the
investigational product, informed consent of subjects, ethical compliance and
approval, qualified medical physician and clinical staff. The aim of imposing
informed consents in the guidelines is to protect the integrity, rights, safety
and confidentiality of trial participants. Also as per ICH-GCP, the product
under study is manufactured as per GMP i.e. Good Manufacturing Practices.
• Clinical trial information and records are easily retrievable and accessible for
accuracy, interpretation and verification of the reports. The subjects and
regulatory authorities have to be informed of premature termination or
suspension of any trial with an explanation. In case of any
compensation, the method and manner of which should meet regulatory
requirements.
38
39. • To avoid any malpractices and overcome inconsistencies in clinical trial, the International
Conference for Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use (ICH) issued these guidelines. The Nuremberg Code, the Declaration of
Helsinki, the Belmont Report, International Conference on Harmonization (ICH-GCP) Code of
Federal Regulations have provided the foundation for the guidelines that have formed the
basis of the ICH-GCP. Pharmaceutical companies and representatives of authorities of
European Union, United States, Japan, Australia, Canada, the Nordic countries and WHO are
enforced to follow these guidelines. The guidelines provide a unified standard in these
regions for mutual acceptance of clinical information and data by the regulatory bodies or
authorities.
• Good Clinical Practice (GCP) is an international, scientific, ethical and harmonised standard
for conducting, monitoring, auditing, recording and reporting in clinical trials. It assures to
report and record results or data of trial subjects with accuracy and protects their integrity,
rights and confidentiality. ICH-GCP represents quality standards that improve data quality,
minimise unwanted exposure of humans to investigational products, enhance marketing
prospects of new drugs and makes trials cost-effective for sponsors. The regulatory bodies,
sponsors, investigators, project monitors, patients, ethical committee or review board are
required to be aware of ICH-GCP.
39
40. • The ICH topics are divided into four categories and ICH topic
codes are assigned according to these categories:
• Q : Quality Guidelines
• S : Safety Guidelines
• E : Efficacy Guidelines
• M : Multidisciplinary Guidelines
40
42. • In an effort to overcome international GCP inconsistencies throughout the
countries, the International Conference for Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH)
issued the ICH Guidelines: Topic E6 Guideline for GCP. This guideline was
approved on 17 July 1996 and implemented for clinical trials from 17
January 1997. The participants of these guidelines were representatives of
authorities and pharmaceutical companies from the EU, Japan and the
United States as well as those of Australia, Canada, the Nordic countries
and WHO. This guideline was approved on 17 July 1996 and implemented
for clinical trials from 17 January 1997. The participants of these guidelines
were representatives of authorities and pharmaceutical companies from the
EU, Japan and the United States as well as those of Australia, Canada, the
Nordic countries and WHO
42
